Open Access

lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis

  • Authors:
    • Jiajie Qian
    • Alok Garg
    • Fuqiang Li
    • Qianyun Shen
    • Ke Xiao
  • View Affiliations

  • Published online on: September 25, 2020     https://doi.org/10.3892/ijo.2020.5128
  • Pages: 1157-1168
  • Copyright: © Qian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is a tumor type characterized by high patient morbidity and mortality. It has been reported that long non‑coding (lncRNA) LUNAR1 (LUNAR1) participates in the regulation of tumor progression, such as diffuse large B‑cell lymphoma. However, its role and underlying mechanisms in CRC progression have not been elucidated. The present study was designed to investigate the underlying mechanisms by which LUNAR1 regulates CRC progression. RT‑qPCR and Pearson's correlation analysis revealed that LUNAR1 was highly expressed and was negatively associated with the overall survival of CRC patients. Moreover, CCK‑8, clone formation, wound‑healing migration, Transwell chamber and FACs assay analyses showed that LUNAR1 knockdown inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. Additionally, LUNAR1 was found to function as a sponge of miR‑495‑3p, which was predicted by TargetScan and confirmed by luciferase reporter assay. Furthermore, functional studies indicated that miR‑495‑3p overexpression inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. In addition, bioinformatics and luciferase reporter assays showed that miR‑495‑3p was found to negatively target Myc binding protein (MYCBP), and functional research showed that LUNAR1 accelerated CRC progression via the miR‑495‑3p/MYCBP axis. In conclusion, LUNAR1 accelerates CRC progression via the miR‑495‑3p/MYCBP axis, indicating that LUNAR1 may serve as a prognostic biomarker for CRC patients.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 57 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qian J, Garg A, Li F, Shen Q and Xiao K: lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis. Int J Oncol 57: 1157-1168, 2020
APA
Qian, J., Garg, A., Li, F., Shen, Q., & Xiao, K. (2020). lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis. International Journal of Oncology, 57, 1157-1168. https://doi.org/10.3892/ijo.2020.5128
MLA
Qian, J., Garg, A., Li, F., Shen, Q., Xiao, K."lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis". International Journal of Oncology 57.5 (2020): 1157-1168.
Chicago
Qian, J., Garg, A., Li, F., Shen, Q., Xiao, K."lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis". International Journal of Oncology 57, no. 5 (2020): 1157-1168. https://doi.org/10.3892/ijo.2020.5128